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The regional distribution of white matter (WM) abnormalities in schizophrenia remains poorly understood, and reported disease
effects on the brain vary widely between studies. In an effort to identify commonalities across studies, we perform what we believe is
the first ever large-scale coordinated study of WMmicrostructural differences in schizophrenia. Our analysis consisted of 2359 healthy
controls and 1963 schizophrenia patients from 29 independent international studies; we harmonized the processing and statistical
analyses of diffusion tensor imaging (DTI) data across sites and meta-analyzed effects across studies. Significant reductions in
fractional anisotropy (FA) in schizophrenia patients were widespread, and detected in 20 of 25 regions of interest within a WM
skeleton representing all major WM fasciculi. Effect sizes varied by region, peaking at (d=0.42) for the entire WM skeleton, driven
more by peripheral areas as opposed to the core WM where regions of interest were defined. The anterior corona radiata (d=0.40)
and corpus callosum (d=0.39), specifically its body (d=0.39) and genu (d=0.37), showed greatest effects. Significant decreases, to
lesser degrees, were observed in almost all regions analyzed. Larger effect sizes were observed for FA than diffusivity measures;
significantly higher mean and radial diffusivity was observed for schizophrenia patients compared with controls. No significant effects
of age at onset of schizophrenia or medication dosage were detected. As the largest coordinated analysis of WM differences in a
psychiatric disorder to date, the present study provides a robust profile of widespread WM abnormalities in schizophrenia patients
worldwide. Interactive three-dimensional visualization of the results is available at www.enigma-viewer.org.
Molecular Psychiatry advance online publication, 17 October 2017; doi:10.1038/mp.2017.170
INTRODUCTION
Schizophrenia, a debilitating psychiatric disorder with a consider-
able societal burden, has been a major focus of neuroimaging
studies for decades, yet its neurobiology remains only partially
understood.1 Cumulative evidence has led to a dysconnectivity
hypothesis—that schizophrenia may involve abnormal or ineffi-
cient communication between functional brain regions,2 and
disturbances in the underlying pattern of white matter (WM)
structural organization.3–5 Genetic and histopathological studies
reveal oligodendrocyte and myelin abnormalities in
schizophrenia.4,6,7 Furthermore, WM genetic variants have been
found to overlap with genes associated with liability for
schizophrenia.8 However, consistent alterations in WM micro-
structure have been difficult to identify. Diffusion tensor imaging
(DTI) allows for the in vivo study of WM microstructural properties
that cannot be made with standard magnetic resonance imaging
alone. DTI has revealed WM changes beyond volumetric
differences in unmedicated, first-episode and chronically affected
schizophrenia patients,9,10 but the anatomical scope and strength
of these effects varies widely across studies.11
WM disruptions in DTI studies of schizophrenia patients are
commonly identified, with significantly lower fractional anisotropy
(FA) in patients compared with controls. Generally, findings have
implicated prefrontal and temporal lobes,5,12,13 and the fiber tracts
connecting these regions.14 Abnormalities have been linked to
cognitive deficits and symptoms in schizophrenia, including
memory impairment and auditory hallucinations.13,15 However,
the considerable heterogeneity in both the effect sizes and the
regional distribution of FA reduction reported across studies have
limited the conclusions drawn to date. In a review by Kanaan
et al.,3 all studies included reported altered FA in schizophrenia
patients, but the specific regions implicated were highly equivocal:
each region implicated had a roughly equal chance of being
identified versus not in a given study. It also remains unclear
whether WM abnormalities are localized to specific tracts or
distributed throughout the brain, and whether specific networks
are differentially disrupted.11,16
Sources of heterogeneity between studies may be attributed to
imaging protocols, scanner differences, differences in patients’
ages at time of scanning, age at illness onset, duration of illness,
symptom severity, medications and other variations in demo-
graphic and socioeconomic factors. Study samples also vary in size
that alone may have a significant effect on the reported findings.17
These factors may modulate the degree of WM abnormalities
detectable with DTI.10
To address the variations in methods, and boost statistical
power, the Schizophrenia Working Group of the Enhancing
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Neuroimaging Genetics through Meta-Analysis consortium
(ENIGMA-Schizophrenia) initiated the first worldwide initiative to
pool effect sizes from a harmonized, coordinated DTI analysis. Our
primary goal was to identify WM microstructural measures derived
from DTI with the most robust disease effects. Focusing on FA, and
further exploring DTI-derived diffusivity measures of both whole-
brain and atlas-defined WM regions of interest (ROIs), we
coordinated a large-scale meta-analysis using the established
ENIGMA-DTI protocol to harmonize the processing of diffusion
data from multiple sites (http://enigma.usc.edu/ongoing/dti-work
ing-group/).18–20 These analytic techniques enable a coordinated
meta-analysis of independent samples worldwide with an effort to
remove biases in pooling, in contrast to retrospective meta-
analyses based on published findings.
We set out to identify consistent and robust WM differences
between individuals with schizophrenia and healthy controls in an
unprecedented sample of 4322 individuals scanned across 29
cohorts from Australia, Asia, Europe, South Africa and North
America. We hypothesized moderate effect sizes across the brain,
based on previous volumetric findings;21 yet we aimed to order
regions according to consistency and magnitude of effect size,
thereby regionally identifying WM that is most severely disrupted
in schizophrenia. We aimed to also determine whether disease-
related factors (including duration of illness, age at onset of
schizophrenia, antipsychotic medication, smoking and severity of
positive and negative symptoms) are also associated with
differences in WM microstructure.
MATERIALS AND METHODS
Study samples
The ENIGMA-Schizophrenia DTI working group currently comprises 29
cohorts from 14 countries totaling 2359 healthy controls and 1963
individuals with schizophrenia (see Supplementary Figure 1).
The mean age across samples was 36.14 years for controls (range: 18–
86) and 36.22 years for patients (range: 18–77). Samples of controls and
patients were ∼ 53.4% and 67% males respectively, but effects of sex were
also modeled. The mean age at onset and duration of illness across the
patient groups were 23 and 14 years, respectively. The mean total Positive
and Negative Syndrome Scale (PANSS) and Scale for the Assessment of
Positive and Negative Symptoms (SANS and SAPS) across the samples
were 55.90, 16.72 and 13.70, respectively. For samples that recorded
current antipsychotic type and dose, the fraction of patients on second-
generation antipsychotics (atypical) was 71%, first generation (typical) was
6%, both 10% and neither 13%. As in van Erp et al.,21 chlorpromazine (CPZ)
equivalents were computed using methods previously described in Woods
(2005; http://www.scottwilliamwoods.com/files/Equivtext.doc). The mean
CPZ dose equivalent across the samples was 371.23. Supplementary Tables
2 and 3 summarize key clinical and demographic information. Each study
sample had been assessed with participants’ written informed consent
approved by local institutional review boards. Individuals with bad-quality
diffusion images were excluded from the analysis.
Imaging acquisition and processing
Details of study type, scanner and acquisition parameters for each of the
29 sites are provided in Supplementary Table 1. Preprocessing, including
eddy current correction, echo-planar imaging-induced distortion correc-
tion and tensor fitting, was carried out at each site. Recommended
protocols and procedures as well as quality control pipelines are available
as part of the ENIGMA-DTI webpage and NITRC (Neuroimaging Informatics
Tools and Resources Clearinghouse). Harmonization of preprocessing
schemes was not enforced across sites to allow individual sites to use
existing pipelines that may be more appropriate for their data acquisition.
Once tensors were estimated, harmonized image analysis of DTI measure
of FA was conducted at each site using the ENIGMA-DTI protocol (see
Supplementary Note 1). As part of a secondary analysis, mean diffusivity
(MD), axial diffusivity (AD) and radial diffusivity (RD) images were also
derived. The present analysis combined ROIs across both hemispheres to
avoid any potential issues of left/right flipping. Lateralized results are
reported in Supplementary Table 4 and Supplementary Note 5 but should
be interpreted with caution.
Statistical analysis
Per-site analysis. We evaluated FA, and available MD, AD and RD
differences between schizophrenia cases and healthy controls by
calculating Cohen’s d effect size estimates for diagnosis of schizophrenia
in each of the 25 ROIs listed in Table 1.
To tease apart regional WM effects from global differences, post hoc
analyses were carried out to covary for the effects of global FA measures
across the entire skeleton, including average FA across the full skeleton,
the central, or ‘core’ FA comprising the average of all voxels in the JHU
(Johns Hopkins University) ROIs, and the peripheral regions defined as
everything besides the core (non-JHU) in the full skeleton analyzed (see
Supplementary Note 2 for calculations of core and periphery FA).
Cohen’s d effect sizes were also calculated for differences in FA between
patients on atypical antipsychotics, typical antipsychotics, both and
unmedicated. Differences in FA were assessed between subgroups of
patients who were smokers versus nonsmokers. Multiple linear regressions
were performed to examine the effects of age at onset, duration of illness,
CPZ scores, PANSS total, positive and negative scores and SAPS and SANS
total scores. Age, sex, age-by-sex interaction and quadratic covariates of
age2 and age2-by-sex interaction were modeled as linear and nonlinear
age and sex interactions have been reported for FA.22 As age and duration
of illness are collinear, we also examined duration of illness in years
without covarying for age, as well as duration expressed as the percent of a
person’s lifetime they had been ill. Interaction effects, including diagnosis
by sex and diagnosis by age, were also calculated. A minimum of 10
subjects per group was used as the cutoff for inclusion in the statistical
analyses. An independent t-test between s.d. measures for average FA
between patients (s.d. = 0.0176) and controls (s.d. = 0.0194) revealed no
significant difference in variance between the groups (P40.0.5).
Code availability
All analyses were conducted using generalizable scripts available on the
ENIGMA-GitHub https://github.com/ENIGMA-git/ENIGMA/tree/master/
WorkingGroups/EffectSize_and_GLM. Individual sites downloaded a single
set of R scripts and specified the set of regressions that were customized
for the current ENIGMA-Schizophrenia DTI analysis, publicly available on a
set of Google Spreadsheet configuration files. Standardized regression
outputs were then uploaded to a central server for meta-analysis.
Meta-analysis
As in prior ENIGMA disease working group meta-analyses,21,23–25 a
random-effects inverse-variance weighted meta-analysis was conducted
at a central coordinating site (the University of Southern California Imaging
Genetics Center) in R (metafor package, version 1.99–118 http://www.
metafor-project.org/) to combine individual site effect sizes (See
Supplementary Note 3). Heterogeneity scores (I2) for each test were also
computed, indicating the percent of the total variance in effect size
explained by heterogeneity of the effects alone. Lower values of I2 indicate
lower variance in the effect size estimates across studies.
Effect sizes are reported as overall Cohen’s d values for case/control
effects and Z-scores for quantitative effects from linear regressions. To
control the reporting of false positives from multiple tests across the ROIs,
for our primary analysis of FA differences in cases as compared with
controls, effects were declared to be significant if they survived the
Bonferroni correction threshold of 0.05/25= 0.002.
RESULTS
FA differences between schizophrenia patients and controls
Of the 25 regions, 20 showed significantly lower FA in patients.
Based on previous meta-analysis5 we hypothesized that WM tracts
interconnecting the frontal lobe, thalamus, cingulate gyrus and
regions of the temporal lobe would be most severely affected. The
largest effect size was observed for lower average FA (across the
whole-brain WM skeleton) in schizophrenia patients, followed by
the anterior corona radiata (ACR), the whole corpus callosum (CC),
body of the CC and the genu of the CC (GCC). Significant patient
reductions were also found in a further 15 ROIs (see Figure 1,
Table 1 and Supplementary Figure 5).
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MD and RD differences between schizophrenia patients and
healthy controls
A secondary analysis was carried out using established measures
of WM diffusivity (MD, AD and RD) for all 29 cohorts. Patients had
significantly higher MD across 17 ROIs and significantly higher RD
across 21 ROIs. Effects observed were larger and more widespread
for RD. Finally, patients had significantly higher AD in the fornix in
comparison with healthy controls (Figure 2, Supplementary
Figures 6).
Sex differences
To examine differences between males and females in relation to
diagnosis, sex-by-diagnosis interactions were conducted.
Although we did not detect a significant interaction effect, we
observed significant differences in effect size when analyzing
males and females separately, with females showing significantly
larger effects for decreased FA (t =− 10.83, P= 0.001) in compar-
ison with males, as seen through a paired t-test. See
Supplementary Figures 10 and 11 and Supplementary Note 6.
Controlling for average, core and peripheral FA
To tease apart regional WM effects from the global differences, a
post hoc analysis was conducted in individual tract ROIs (as
previously performed) but additionally covarying for (1) average
FA across the entire skeleton (the average FA contains both core
and periphery voxels), (2) average FA within the core of the
skeleton only, within which ROIs are defined as part of the JHU
atlas or (3) the average FA within the periphery of the skeleton
only—areas on the skeleton not included in the ROIs of the JHU
atlas (non-JHU).
Covarying for average FA, there is significantly increased FA in
the posterior limb of internal capsule (PLIC) only (Po0.002). After
covarying for core FA, there is significantly decreased average FA,
body of corpus callosum, fornix, CC and anterior limb of internal
capsule (ALIC), as well as increased FA in the PLIC (Po0.002).
Finally, after covarying for periphery FA, no effects remain
significant after multiple comparison correction (Po0.05), sug-
gesting the effects are being driven by the peripheral WM regions
and no individual ROI in the core of the WM goes significantly
above and beyond those effects. See Supplementary Figures 2.
Association of clinical traits with FA
Age by diagnosis. To examine differences in the effects of age on
FA between patients and controls, we performed age-by-diagnosis
interaction tests for each ROI. A significant age-by-diagnosis
interaction was observed in the ACR (β=− 0.00037, P= 0.0001)
and across the average FA skeleton (β=− 0.00018, P= 0.0003),
with patients showing accelerated FA reductions with age (see
Supplementary Figure 12).
Duration of illness and age at onset
To investigate whether WM microstructure may change with
illness duration, reflecting a progressive disease process, we
conducted correlations between duration of illness and FA for
patients across all ROIs. We found a significant inverse association
between FA and duration of illness in years for 10 of the 25 ROIs
(see Table 2), without age included in the regression model
(N= 1178, 20 sites). When covarying for age, the relationship
between duration of illness and FA is nonsignificant. No significant
association between FA and duration of illness expressed as a
percentage was observed. Similarly, no significant associations
between FA and age at onset of schizophrenia were observed
(N= 1161, 20 cohorts).
Symptom severity
To investigate whether WM changes were associated with positive
and negative symptom severity in schizophrenia, we conducted
correlations between symptom severity scores—as measured by
PANSS positive, PANSS negative, SAPS and SANS—and FA across
all ROIs. Trending negative correlations were observed between
SANS total scores (N= 433, 9 cohorts) and FA of the ALIC, CC,
cingulum, IC and posterior thalamic radiation, as well as between
SAPS total scores (N= 406, 9 cohorts) and FA of the CC and GCG,
but the effects did not survive correction for multiple compar-
isons. Trending negative associations were also observed between
PANSS negative (N= 674, 10 cohorts) scores in the ALIC, IFO,
posterior thalamic radiation and SCC and PANSS total scores
(N= 695, 10 cohorts) in the ALIC, CC, SCC and SCR. Similarly, these
effects did not survive correction for multiple comparisons (see
Supplementary Tables 5 and 6).
Medication and smoking
To assess the potential impact of antipsychotic medication on WM
changes in schizophrenia, we carried out correlations between
CPZ equivalent scores (Woods, 2005, http://www.scottwilliam
woods.com/files/Equivtext.doc) and FA. No significant associations
between FA and CPZ scores were detected (N= 627, 10 cohorts).
The current study was underpowered to compare patients based
on their atypical or typical antipsychotic use in a multisite
framework and therefore we decided to omit this from the
analysis. Using a cutoff of N= 10 per group, only 31 patients from
Table 1. Cohen’s d values, their s.e., P-values and I2 (heterogeneity)
values after meta-analysis for FA differences between schizophrenia
patients and healthy controls
ROI Cohen’s d s.e. P-value I2 N voxels
Average FA − 0.42 0.042 4.5 × 10− 24 34.65 112 889
ACR − 0.40 0.045 9.19 × 10− 19 43.83 3129
CC − 0.40 0.045 8.36 × 10− 19 42.51 7318
BCC − 0.39 0.045 2.51 × 10− 18 43.24 3173
GCC − 0.37 0.042 1.24 × 10− 18 35.22 1834
ALIC − 0.37 0.046 2.27 × 10− 15 46.30 1510
CR − 0.33 0.040 3.16 × 10− 17 27.89 7344
FXST − 0.32 0.042 8.28 × 10− 14 36.39 706
FX − 0.31 0.045 6.76 × 10− 12 43.25 222
PTR − 0.31 0.035 1.99 × 10− 18 11.78 1987
SS − 0.30 0.040 4.91 × 10− 14 30.34 1294
SFO − 0.29 0.054 3.96× 10− 8 59.68 193
CGC − 0.27 0.045 2.95× 10− 9 42.87 594
PCR − 0.25 0.036 2.39 × 10− 12 15.76 1437
SCC − 0.22 0.048 4.39× 10− 6 50.94 2311
SLF − 0.22 0.040 5.61× 10− 8 29.17 3503
EC − 0.21 0.040 1.41× 10− 7 31.01 2896
IC − 0.18 0.042 1.80× 10− 5 36.25 4781
UNC − 0.16 0.033 8.78× 10− 6 4.18 125
SCR − 0.15 0.034 6.91× 10− 6 7.84 2778
RLIC − 0.13 0.041 0.0021 33.10 1496
IFO − 0.11 0.038 0.0035 22.70 88
CGH − 0.11 0.041 0.0082 33.73 524
CST − 0.04 0.038 0.24 24.20 167
PLIC 0.04 0.046 0.37 46.20 1775
Abbreviations: ACR, anterior corona radiata; ALIC, anterior limb of internal
capsule; BCC, body of corpus callosum; CC, corpus callosum; CGC,
cingulum; CGH, cingulum (hippocampal portion); CR, corona radiata; CST,
corticospinal tract; EC, external capsule; FA, fractional anisotropy; FX, fornix;
FXST, fornix stria terminalis; GCC, genu of corpus callosum; IC, internal
capsule; IFO, inferior fronto occipital fasciculus; PCR, posterior corona
radiata; PLIC, posterior limb of internal capsule; PTR, posterior thalamic
radiation; RLIC, retrolenticular part of IC; ROI, region of interest; SCC,
splenium of corpus callosum; SCR, superior corona radiata; SFO, superior
fronto-occipital fasciculus; SLF, superior longitudinal fasciculus; SS, sagittal
stratum; UNC, uncinate.
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two cohorts were taking both typical and atypical medication, 27
patients from 2 cohorts were taking typical antipsychotics only
and 68 patients from 4 cohorts were unmedicated. The majority of
patients (N= 486 across 10 cohorts) were taking atypical
antipsychotics. Finally, to investigate the effects of nicotine intake
on WM in schizophrenia, we examined differences between
smokers and nonsmokers in the patient group. No significant
differences in FA between smokers and nonsmokers in the patient
group were observed. There were 248 nonsmoker patients and
260 smoker patients across 6 cohorts.
DISCUSSION
In the largest coordinated meta-analysis to date—evaluating DTI
data from 1963 individuals with schizophrenia and 2359 healthy
participants—we found a highly consistent pattern of affected
WM in cohorts recruited around the world. FA was lower for
patients globally across the whole-brain WM skeleton and
significantly detected in 19 out of 24 tract-based ROIs, including
the CC (specifically body and genu), the CR (anterior, posterior and
superior), ALIC, fornix, posterior thalamic radiation, superior
fronto-occipital fasciculus, sagittal stratum, cingulum, superior
Figure 1. (a) Fractional anisotropy (FA) differences between schizophrenia patients and healthy controls for 25 white matter (WM) regions
representing major fasciculi. Gradient bar indicates Cohen’s d effect sizes after meta-analysis. (b) Cohen’s d effect sizes after meta-analysis,
sorted in increasing magnitude of Cohen’s d effect sizes across 29 cohorts for FA differences in schizophrenia patients (N= 1963) versus
healthy controls (N= 2359), after including age, sex, age × sex, age2 and age2 × sex as covariates. Error bars represent 95% confidence intervals.
Significant regions after adjusting for multiple regions tested (Po0.05/25= 0.002) are highlighted in orange. (c) Forest plot of effect sizes for
29 cohorts. Interactive three-dimensional (3D) visualization of the results is available at www.enigma-viewer.org.
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longitudinal fasciculus, external capsule, IC and uncinate (see
Table 1). Largest effects were observed for whole brain average
FA, ACR, CC, body of corpus callosum, genu of the CC and ALIC, all
showing Cohen’s d magnitudes of 40.35 (medium effect sizes,
according to Cohen’s criteria26). When controlling for global
effects, none of the individual tract regions showed significant
case/control associations beyond those detected globally, with
the exception of increased FA in the PLIC for patients. Widespread
increases in mean and radial diffusivity for patients were also
observed, as well as a subtle increase in axial diffusivity of the
fornix. This ranking of regions may guide and inform future
studies of schizophrenia with DTI. The current sample size is also
well powered to detect Cohen’s d values as small as 0.10 (see
Supplementary Note 4 and Supplementary Table 7). Similar
magnitudes of effect were also observed in a prior coordinated
meta-analysis of subcortical volumes in schizophrenia21 where
effects ranged from − 0.46 to − 0.37. The uniform direction and
widespread distribution of these differences may support the
concept of schizophrenia as a disorder of global structural
dysconnectivity. Schizophrenia as a disorder that affects WM
globally is supported by recent studies of the human connectome
indicating that although long-range WM connections between
brain hubs are most severely disrupted in the disorder,
connectivity deficits are widespread and span virtually the entire
connectome.16,27 The assumption of global (instead of localized)
FA deficits in schizophrenia has also been supported by
alternative analytical approaches based on systematic resampling
of an original data set.17
In the context of a structural dysconnectivity hypothesis in
schizophrenia, we were able to provide a more accurate estimate
of WM alterations in the disorder. We analyzed data from 29
cohorts with a total sample of 4322 individuals using a common
analysis pipeline we had previously developed.18–20 This allowed
for a coordinated prospective meta-analysis of the data, unlike
traditional meta-analyses that attempt to combine statistical
results from the literature. This approach addresses, for we believe
the first time, issues of low power and inconsistencies of analysis
that have contributed to the heterogeneity and ambiguity in
results of DTI studies in schizophrenia to date.
Figure 2. (a) Cohen’s d effect sizes, after meta-analysis, for fractional anisotropy (FA), mean diffusivity (MD) and radial diffusivity (RD)
differences in schizophrenia patients versus healthy controls, after including age, sex, age × sex, age2 and age2 × sex as covariates for the top
four regions of interest (ROIs) showing the largest FA effects (average FA, body of corpus callosum (BCC), corpus callosum (CC), anterior corona
radiata (ACR) and genu of corpus callosum (GCC)). Error bars represent the 95% confidence intervals. The corpus callosum, ACR and FA across
the whole brain are among the measures that show most robust effects in cohorts worldwide. (b) Relationship between FA and diffusivity
(mean, axial and radial) Cohen’s d effect sizes after meta-analysis for differences between schizophrenia patients and healthy controls. The
effect of RD is highly correlated, whereas axial diffusivity (AD) shows no correlation and low effect sizes.
Table 2. Regression β-values, s.e. and P-values after meta-analysis for
FA associations with duration of illness in years including sex as a
covariate
Region Z-score β-Value s.e. P-value
ACR − 4.04 − 0.001013 0.00054 0.071
ALIC −3.77 −0.000512 0.00041 1.66×10−9
Average FA − 7.08 − 0.000476 0.00024 0.0094
BCC −1.78 −0.001170 0.00024 9.33× 10−19
CC −3.34 −0.000836 0.00026 7.24× 10-6
CGC −7.67 −0.000761 0.00014 2.5 ×10−13
CGH − 4.58 0.000101 0.00020 0.65
CR − 4.19 − 0.000702 0.00019 0.12
CST − 7.64 0.000042 0.00013 0.95
EC −6.14 −0.000528 0.00047 2.45× 10−10
FX − 0.72 − 0.002240 0.00011 0.0003
FXST −1.90 −0.000673 0.00010 2.26×10−5
GCC − 3.42 − 0.001011 0.00013 0.033
IC − 5.27 − 0.000348 0.00045 0.11
IFO − 3.77 − 0.000164 0.00063 0.72
PCR − 2.75 − 0.000573 0.00008 0.0052
PLIC − 3.60 − 0.000222 0.00057 0.4
PTR −2.82 −0.001138 0.00011 3.03×10−7
RLIC − 3.87 − 0.000584 0.00043 0.024
SCC −5.02 −0.000600 0.00019 1.29×10−8
SCR − 2.80 − 0.000499 0.00025 0.24
SFO − 3.05 − 0.000599 0.00030 0.078
SLF −6.76 −0.000600 0.00012 2.10× 10−15
SS −2.37 −0.000913 0.00009 2.62× 10−24
UNC −0.65 −0.000871 0.00028 5.20×10−8
Abbreviations: ACR, anterior corona radiata; ALIC, anterior limb of internal
capsule; BCC, body of corpus callosum; CC, corpus callosum; CGC,
cingulum; CGH, cingulum (hippocampal portion); CR, corona radiata; CST,
corticospinal tract; EC, external capsule; FA, fractional anisotropy; FX, fornix;
FXST, fornix stria terminalis; GCC, genu of corpus callosum; IC, internal
capsule; IFO, inferior fronto occipital fasciculus; PCR, posterior corona
radiata; PLIC, posterior limb of internal capsule; PTR, posterior thalamic
radiation; RLIC, retrolenticular part of IC; SCC, splenium of corpus callosum;
SCR, superior corona radiata; SFO, superior fronto-occipital fasciculus; SLF,
superior longitudinal fasciculus; SS, sagittal stratum; UNC, uncinate.
Significant regions (Po0.05/25= 0.002) are highlighted in bold.
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Regional specificity of WM findings in schizophrenia
The most consistent findings in the schizophrenia literature until
now have included aberrant interhemispheric and fronto-
temporal connectivity.5,12,13 Magnetic resonance imaging studies
show smaller volume of the CC and its subregions in chronic, first-
episode and high-risk individuals, suggesting that it is a stable
feature of the disorder.28–30 Reduced FA of the CC was also
reported in a prior retrospective meta-analysis of 15 DTI studies in
schizophrenia5 and a meta-analysis of studies examining both
gray and WM.31 These findings suggest that abnormal interhemi-
spheric communication may play a role in the etiology of
schizophrenia.
WM FA differences in the ALIC and ACR are consistently
reported in schizophrenia.32,33 The ALIC connects the thalamus
and prefrontal cortex and FA of this region has been shown to be
correlated with verbal and nonverbal episodic memory in single-
site studies of schizophrenia.32,33 In line with prior DTI studies, we
report significantly decreased FA for the ALIC and not the PLIC.33
The corona radiata contains reciprocal connections from the
thalamus to the cerebral cortex and is thought to be involved in
information processing. Reductions in FA of this pathway have
been associated with increased severity of auditory verbal
hallucinations in schizophrenia.34 A medium effect was also
observed for the fornix, a structure implicated in cognitive
disturbances and memory function in schizophrenia.35 A subtle
increase in axial diffusivity for patients was also observed
in this region. The fornix is particularly vulnerable to partial
volume effects, and hence WM measures in this region are
inconsistent.36,37 Therefore, the current findings in the fornix
should be interpreted with caution. Reliability estimates for all
ROIs are reported in the Supplementary Tables 8.
Although the largest effects were observed for WM tracts of
frontotemporal, interhemispheric and corticothalamic regions, the
current findings suggest a global mechanism for WM dysconnec-
tivity in schizophrenia. After controlling for average and periphery
FA, non-significant differences are observed for almost all ROIs,
with the exception of increased FA in the PLIC for patients,
suggesting that the effect for average FA of the WM skeleton is
driving the difference in FA across almost all of the ROIs. Patterns
of widespread FA decreases and localized FA increases have been
previously found in schizophrenia, with the latter thought to be a
result of aberrant axonal pruning.16,38
Demographic and clinical correlates of WM changes in
schizophrenia
No significant sex-by-diagnosis interactions were observed in the
current analysis, but females had significantly larger effect sizes for
lower FA overall. Post-mortem studies suggest that WM abnorm-
alities are more pronounced in female patients39,40 and an in vivo
DTI analysis41 reported decreased FA in the CC for female patients
compared with males. The etiology of these sex differences is
unclear, but the findings suggest subtle sex-dependent alterations
of WM in schizophrenia.
Duration of illness was negatively correlated with FA in 10 of the
25 WM ROIs. As duration of illness is highly correlated with age,
these effects are hard to separate. After covarying for age, the
relationship between FA and duration of illness is no longer
significant. Longitudinal analyses of first-episode, high-risk and
chronic patients are needed to distinguish effects of age and
duration of illness. Significant age-by-diagnosis interactions were
found in the ACR and across the average FA. Unlike previous
findings,42 Kochunov et al.43 report similar age-by-diagnosis
interactions in these regions, indicating that schizophrenia
patients are more susceptible to faster age-related decline in FA
values of WM regions that mature later in life.
Trend-wise negative relationships between positive and nega-
tive symptom severity scores and WM FA of regions of the CC, IC
and thalamic radiations were also observed. WM integrity of these
regions has previously been associated with severity of positive,
negative and cognitive symptoms.33,44–46 Parsing these measures
based on the individual items of the positive and negative
symptom scales may reveal more robust associations with WM FA.
No significant effects of age at onset of schizophrenia or
medication dosage were detected in the current study. Many
cross-sectional DTI studies report no detectable correlations
between medication and anisotropy.10,47
Biological basis of WM abnormalities
This study confirms a brain-wide pattern of reduced FA and focal
increased FA in schizophrenia, with the latter hypothesized to
occur as a consequence of aberrant axonal pruning.16,38 By
evaluating WM on a common skeleton, we are able to focus on
microstructural differences independent of gray matter volumetric
abnormalities. In comparing our findings with the ENIGMA-
Schizophrenia study of subcortical volumes,21 we note that the
maximal effect sizes are similar (Cohen’s d ∼− 0.4), yet in that
work, effects were found to be specific to certain subcortical
structures including the hippocampus, amygdala and thalamus,
whereas structures of the basal ganglia, including the caudate,
putamen and pallidum, showed no effect. This implies more
global deficiencies in WM whereas volume differences are more
localized, perhaps in part because of the effect of added
comorbidities. In a proof-of-concept work, Franke et al.48 were
unable to find genetic overlap between schizophrenia and
subcortical volumes. It is yet to be determined whether WM,
which is more globally affected, may serve as a more promising
endophenotype. Altered WM connectivity is postulated to play a
significant role in the etiology of schizophrenia, but the
mechanisms leading to altered connectivity remain unknown.
Currently, hypotheses about the causative basis of this dyscon-
nectivity are varied and include changes in oligodendrocyte and
microglial function.49 As noted above, age at onset, duration of
illness (covarying for age) and medication dosage did not explain
a significant proportion of WM variation, suggesting that whatever
the causes, their effects do not overlap exclusively with the period
of clinical diagnosis and treatment. However, WM deterioration
may also be a consequence of the disorder. Cropley et al.50 found
that gray matter volume loss predated WM loss, with accelerated
WM deterioration with age in schizophrenia, detecting significant
WM differences in patients only detected after age 35. Further-
more, Pasternak et al.51,52 found increased free water—a potential
surrogate marker for neuroinflammation—in first-episode schizo-
phrenia, with deterioration in free-water corrected FA in chronic
schizophrenia. These results may indicate that WM abnormalities
may be more pronounced and more widespread in later stages of
the illness and may be predated by gray matter volume loss and
inflammation in earlier stages of the illness. Future analyses of
these data sets will examine available samples of high-risk, first-
episode, early and chronic schizophrenia to assess whether these
WM effects are present before illness onset and whether they
progress throughout the illness.
Study limitations
Despite being the largest of its kind, our study should be
interpreted cautiously. This meta-analysis is cross-sectional and
effects of age, age by diagnosis, along with durations of illness
and/or medication exposure on WM microstructure may be more
thoroughly investigated with a longitudinal design looking at
rates of changes in the microstructural properties. The ENIGMA-
DTI protocol has been validated for longitudinal analyses,53 but
follow-up assessments of patients with diffusion imaging are
limited within the ENIGMA-Schizophrenia Working group cohorts.
This current study is the first to show that effect sizes from
harmonized DTI analyses may be pooled to detect reliable
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microstructural differences in patients from around the world.
Future analyses aimed at harmonizing additional covariates across
the ENIGMA groups may help tease apart effects. For example,
accounting for genetic and environmental factors associated with
schizophrenia, including general health conditions, lifestyle,
additional recreational drugs or medications, trauma and stress,
may add to a deepened understanding of the WM differences
seen in this study.
In general, larger effects were observed in the larger ROIs
containing a greater number of voxels, including the CC, and we
found a medium but nonsignificant correlation between effect
size and the square root of the number of voxels (sqrt(N)) in each
ROI (see Supplementary Note 7). This is an issue that should be
taken into consideration when interpreting regions where
significant effects were not observed. As well as ROI size, we
also investigated whether the number of gradient directions
significantly affected Cohen’s d measures by splitting the
cohorts into high direction (430 directions) and low direction
(o30 directions) groups. We found no significant differences in
Cohen’s d measures between these groups (Supplementary
Figure 9).
Lower FA in coherent fiber bundles may reflect abnormal fiber
coherence or packing, or aberrations of axonal integrity and/or
myelination. Although more detailed histopathological validations
are needed, analyses of other diffusivity measures may help
interpret the underlying microstructural abnormalities. Here we
found widespread increased MD and RD in patients compared
with controls, as well as increased AD in the fornix. This suggests
that the observation of lower FA may be driven mainly by aberrant
myelination across most ROIs, with axonal density reduction in the
fornix, although these imaging-based estimates do not fully
capture the underlying microscopic cellular processes to confirm
this.49
Finally, tract-based spatial statistics (TBSS) is a widely used
method for voxel-based analysis of WM that addresses issues
associated with smoothing and misalignment in DTI group
analysis.54 However, the method has some limitations. TBSS
reduces WM tracts into a skeleton, delineating the center of the
tracts and projecting onto it only the highest value FA along the
projection that results in loss of information55 and potential
artifacts,56 often a result of misregistration. For example, as with
any population study that spatially normalizes brain images,
misalignment can occur; for TBSS however, this can be a particular
problem in the separation of adjacent WM tracts.57 Smaller tracts,
such as the fornix, are more susceptible to misalignment.
Approaches for retrospective multisite analysis of DTI are
extremely limited, yet we, as ENIGMA-DTI, have conducted several
test–retest and reliability analyses to ensure reproducibility of
measures and effects using this TBSS approach.53 Although the
regional analysis conducted here using TBSS is not able to capture
all information regarding brain microstructure, the results from
this work confirm the importance of WM alterations and global
dysconnectivity. This will enable more in-depth studies, including
voxelwise rather than ROI-based analyses and motivate the
harmonization of tractography-based approaches. We hope this
work shows the importance of pooling diffusion magnetic
resonance imaging for large-scale studies and motivates additional
methodological approaches for such multisite work, including
harmonizing connectomic analyses and further evaluating tract-
based measures, such as tract density and cortical connections.
CONCLUSIONS
This study shows robust and widespread WM changes across
multiple regions of interest for schizophrenia patients. Global
microstructural alterations, corresponding to previously reported
gray matter disruptions,31 provide further evidence that schizo-
phrenia may be, in part, a disorder of global brain structural
connectivity. The present study is the largest analysis of WM
differences in schizophrenia to date, and the first to use
harmonized protocols, allowing for more accurate estimates of
effect size. The reported effect sizes also provide important
information for power estimates in schizophrenia imaging studies.
Our consortium is currently applying these methods across
multiple samples of other psychiatric disorders, including major
depression, bipolar disorder and obsessive compulsive disorder,
that will eventually allow for a large-scale cross-disorder
comparison of disease effects on WM (for an overview of ongoing
projects in ENIGMA, see http://enigma.usc.edu). Comparing WM
effects will no doubt shed further light on similarities and
differences in the pathophysiology of these disorders.
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